Invesco
KIN

Invesco’s Kindred Biosciences, Inc. KIN Stock Holding History

Invesco’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-98,312
Closed -$1.08M – 3889
2018
Q4 		$1.08M Sell
98,312
-98,910
-50% -$1.25M ﹤0.01% 2930
2018
Q3 		$2.75M Buy
+197,222
New +$2.67M ﹤0.01% 2541

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Invesco's KIN Position: Q1 2019 in Review

Invesco sold out of Kindred Biosciences, Inc. (KIN) in Q1 2019, closing a stake of 98,312 shares — an estimated $1.08M sold.

Invesco first reported a position in KIN in Q3 2018 and held it in 2 quarters. The position peaked at $2.75M in Q3 2018. 75 funds tracked by Wall St. Rank hold KIN as of Q1 2019.

  • Invesco reported no remaining Kindred Biosciences, Inc. position as of Q1 2019 after selling out during the quarter.
  • Invesco sold 98,312 Kindred Biosciences, Inc. shares in Q1 2019, an estimated $1.08M.
  • Invesco first reported a position in Kindred Biosciences, Inc. in Q3 2018 and held it in 2 quarters.
  • Invesco's Kindred Biosciences, Inc. position peaked at $2.75M in Q3 2018.
  • 75 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q1 2019.

Based on Invesco's 13F filing for Q1 2019, filed 15 May 2019.